US Pharma MarketingCellares rebukes Bristol Myers
Cellares cuts 100 jobs after Bristol Myers ends Breyanzi manufacturing deal; startup disputes claims its Cell Shuttle tech fell short. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in…
Cell therapy manufacturing startup Cellares is defending itself against Bristol Myers Squibb after the drugmaker pulled out of a contract claiming Cellares’ commercial manufacturing technology was not up to scratch.
Due to the partnership ending ...
Source: Endpoints News